Antengene Corporation Ltd
HKEX:6996
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Antengene Corporation Ltd
Accounts Receivables
Antengene Corporation Ltd
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Antengene Corporation Ltd
HKEX:6996
|
Accounts Receivables
¥27.5m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Accounts Receivables
¥3.1B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Accounts Receivables
¥5.1B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
9%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Accounts Receivables
¥10.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
23%
|
CAGR 10-Years
25%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Accounts Receivables
¥3.3B
|
CAGR 3-Years
10%
|
CAGR 5-Years
12%
|
CAGR 10-Years
16%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Accounts Receivables
¥106.7m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
Antengene Corporation Ltd
Glance View
Antengene Corp. Ltd. operates as clinical-stage Asia-Pacific biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-11-20. The firm is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company’s products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The firm mainly conducts its business in Asia-Pacific.
See Also
What is Antengene Corporation Ltd's Accounts Receivables?
Accounts Receivables
27.5m
CNY
Based on the financial report for Dec 31, 2025, Antengene Corporation Ltd's Accounts Receivables amounts to 27.5m CNY.
What is Antengene Corporation Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 3Y
-3%
Over the last year, the Accounts Receivables growth was 47%. The average annual Accounts Receivables growth rates for Antengene Corporation Ltd have been -3% over the past three years .
